30 completed. 30 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 30 | Completed 30 |
| Phase 2 | 10 | Completed 10 |
Follow Staphylococcal Infections: new trials by email Literature Review of Staphylococcal Infections trials Research Report on Staphylococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia AP-SA02, Placebo - Bacteremia, Staphylococcus Aureus | Phase 1 / Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 56 | 2022-04-26 | 2026-03-23 |
| A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection 9MW1411 injection, 9MW1411 injection placebo - Staphylococcus Aureus Infection | Phase 1 | Completed | Mabwell (Shanghai) Bioscience Co., Ltd. | 42 | 2021-04-16 | 2022-06-15 |
| Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers TP-102 - Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection | Phase 1 / Phase 2 | Completed | Technophage, SA | 20 | 2021-03-22 | 2022-10-04 |
| A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7 - Staphylococcus Aureus Infection | Phase 1 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 144 | 2019-05-16 | 2021-03-30 |
| Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Hydroxychloroquine - Hidradenitis Suppurativa, Hidradenitis | Phase 1 / Phase 2 | Completed | Elena Gonzalez Brant, MD | 17 | 2017-09-28 | 2020-04-02 |
| Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis Roseomonas mucosa - Atopic Dermatitis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 31 | 2017-04-20 | 2019-11-27 |
| A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml), Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml), High dosage of Staphylococcus aureus vaccine (60µg/0.6ml) - Staphylococcus Aureus Infection | Phase 1 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 144 | 2016-09-01 | 2017-10-17 |
| Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess Antimicrobial TheraGauze - Furunculosis | Phase 1 / Phase 2 | Completed | Eastern Virginia Medical School | 6 | 2016-04-01 | 2018-10-04 |
| Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects. 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment - Staphylococcus Aureus Bacteremia | Phase 1 / Phase 2 | Completed | XBiotech, Inc. | 52 | 2015-05-01 | 2026-02-09 |
| Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years SA4Ag vaccine, Blood sample - Staphylococcal Infections | Phase 1 | Completed | Pfizer | 100 | 2015-01-01 | 2015-04-03 |
| Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects XF-73 nasal gel, Placebo nasal gel, Chlorhexidine gluconate 2% topical cloths - Staphylococcus Aureus Infection | Phase 1 / Phase 2 | Completed | Destiny Pharma Plc | 60 | 2014-09-01 | 2016-10-07 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects Placebo, MEDI4893 - Staphylococcus Aureus | Phase 1 | Completed | MedImmune LLC | 85 | 2013-01-01 | 2014-07-24 |
| Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 Placebo, XF-73 in 2% Klucel gel, XF-73 in 4% Klucel gel - Staphylococcal Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2012-08-01 | 2016-09-05 |
| Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years SA4Ag vaccine low dose, Blood draw, Colonization swab sample - Staphylococcal Infections | Phase 1 | Completed | Pfizer | 284 | 2012-08-01 | 2019-03-04 |
| Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus) KBSA301, Placebo - Pneumonia Due to Staphylococcus Aureus | Phase 1 / Phase 2 | Completed | Aridis Pharmaceuticals, Inc. | 48 | 2012-05-01 | 2020-04-24 |
| Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, Placebo with alum IM - Staphylococcal Infections, Yeast Infections | Phase 1 | Completed | NovaDigm Therapeutics, Inc. | 164 | 2011-09-01 | 2020-03-04 |
| Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years SA4Ag vaccine low dose, Blood draw, Colonization swab sample - Staphylococcal Infections | Phase 1 | Completed | Pfizer | 456 | 2011-08-01 | 2019-03-04 |
| Phase I STEBVax in Healthy Adults Aluminum hydroxide, STEBVax vaccine - Toxic Shock Syndrome Staphylococcal | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 29 | 2011-02-01 | 2015-06-19 |
| Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida NDV-3 investigational vaccine - Staphylococcal Infections, Candidiasis | Phase 1 | Completed | NovaDigm Therapeutics, Inc. | 40 | 2011-01-01 | 2012-05-22 |
| A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults Staphylococcal investigational vaccine GSK2392103A, Staphylococcal investigational vaccine GSK2392105A, Staphylococcal investigational vaccine GSK2392106A - Infections, Staphylococcal | Phase 1 | Completed | GlaxoSmithKline | 88 | 2010-07-19 | 2017-05-30 |
Showing 20 of 30. Sign in to see all of them.
Staphylococcal Skin Infections (5) · Streptococcal Infections (4) · Bacteremia (2) · Candidiasis (2) · Cellulitis (2) · Furunculosis (2) · Soft Tissue Infections (2) · Acinetobacter Infections (1) · Bacterial Infections (1) · Dermatitis, Atopic (1) · Diabetic Foot (1) · Hidradenitis (1) · Hidradenitis Suppurativa (1) · Motor Activity (1)
Bacterial Infections and Mycoses (30) · Gram-Positive Bacterial Infections (30) · Infections (30) · Bacterial Infections (29) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Skin Diseases, Bacterial (7) · Skin Diseases, Infectious (7) · Inflammation (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Sepsis (3) · Suppuration (3) · Systemic Inflammatory Response Syndrome (3)
Blood Specimen Collection (4) · ceftobiprole (4) · V710 vaccine (2) · Adjuvants, Pharmaceutic (1) · Aluminum Hydroxide (1) · Hydroxychloroquine (1) · Textiles (1) · chlorhexidine gluconate (1) · suvratoxumab (1)
Basilea Pharmaceutica (4) · Pfizer (4) · Merck Sharp & Dohme LLC (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Jiangsu Province Centers for Disease Control and Prevention (2) · NovaDigm Therapeutics, Inc. (2) · Aridis Pharmaceuticals, Inc. (1) · Armata Pharmaceuticals, Inc. (1) · Destiny Pharma Plc (1) · Eastern Virginia Medical School (1) · Elena Gonzalez Brant, MD (1) · GlaxoSmithKline (1) · Henry M. Jackson Foundation for the Advancement of Military Medicine (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1) · MedImmune LLC (1)
United States (15) · China (3) · Australia (2) · Belgium (2) · France (1) · Israel (1) · Spain (1) · United Kingdom (1)
Deborah Birx, MD (1) · Elena M Gonzalez Brant, MD (1) · Fangyue Meng, Master (1) · Hasan Jafri, M.D. (1) · Howard Schwartz, M.D. (1) · Ian A Myles, M.D. (1) · Ian Mr Hayter, BSc (1) · Kenji M Cunnion, M.D., M.P.H. (1) · Mark Rupp, M.D. (1) · Michael L Landrum, MD (1) · Paul Kessler, MD (1)
PMID 31993453, PMID 35473663, PMID 17893153, PMID 20943877, PMID 22192849, PMID 25707693, PMID 25715157, PMID 27519620, PMID 27707765, PMID 27866765, PMID 27916408, PMID 28143674, PMID 30343314, PMID 33873093, PMID 39740667